COGT — Cogent Biosciences
Median target
$55
calls from the last 12 months
Implied return
+65.7%
median target vs. price
Coverage
11 analysts · 11 calls
updated in the last 12 months
Consensus
10/1/0+10 net
Buy / Hold / Sell
Which analysts are behind COGT's consensus?
See every current rating, price target and the analysts' track records for Cogent Biosciences — plus the full analyst rankings, firm analytics and screener.
The consensus above reflects 11 analysts with calls on COGT updated in the last 12 months. Implied return is the move implied if the consensus target were hit. These are forward-looking predictions, not realized returns. Per-analyst ratings and track records are a Premium feature.
COGT elsewhere on AnalystEdge
The most recent congressional, executive-branch and insider filings matched to this ticker. Matched by ticker symbol — occasional mismatches are possible. Not investment advice.
Trending today: not in any of today's trending tables (Gaining attention, Losing attention, Most followed)
| Date | Source | Who | Action | Detail | Amount |
|---|---|---|---|---|---|
| 2026-08-27 | Insiders | Morris ArleneDirector | Insider sale | 42.3K sh @ $37.09 · planned trade | $1.6M |
| 2026-08-27 | Insiders | Morris ArleneDirector | Insider sale | 3.2K sh @ $37.54 · planned trade | $119K |
| 2022-12-12 | Congress | Christopher L. JacobsNY-NY27 | Purchase | since trade +160.3%, vs market +60.3% | $1K–$15K |
More: congressional trades on COGT · insider activity · executive branch · trending